Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double-blind placebo-controlled study

European Psychiatry

Volumn 23, Issue 2, 2008, Pages 109-114

  Aliyev, Nadir A ^a   Aliyev, Zafar N ^a  

^a Mental Clinic for Outpatients of Baku City   (Azerbaijan)

Author keywords

Depakine chrono; Generalized anxiety disorder; Treatment

Indexed keywords

PLACEBO; VALPROIC ACID;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE TEST; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE;

ACUTE DISEASE; ADULT; ANTICONVULSANTS; ANXIETY DISORDERS; AZERBAIJAN; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; TREATMENT OUTCOME; VALPROIC ACID;

EID: 39649096752     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2007.08.001     Document Type: Article

References (43)

1. Baetz M., and Browen R.C. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 43 1 (1998 Feb) 73-77
2. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R.T., et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19 6 (2005) 567-596
3. Balfour J.A., and Bryson H.M. Valproic Acid. A review of its pharmacology and therapeutic potential in indication other than epilepsy. CNS Drug 2 (1994) 144-173
4. Bandelow B., Wedekind D., and Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 7 7 (2007 Jul) 769-781
5. Barre J, Berger Y., Pharmacokinetics of a newly developed sustained release from of sodium valproate. In: Chadwick D, editor. Proceedings of the Four International Symposium on Sodium Vaproate and Epilepsy, International Congress and Symposium Series No 152. Royal Society of Medicine Services, London, 1989.
6. Barros H.M., Tannhauser M.A., and Tannhauser M. Effect of sodium valporate on the open-field behavior of rats. Braz J Med Biol Res 25 3 (1992) 281-287
7. Becker H.C., and Anton R.F. Valproate potentiates and picrotoxin antagonizes the anxiolytic action of ethanol in a nonshock conflict task. Neuropharmacology 29 9 (1990 Sep) 837-843
8. Boulenger J.P., and Capdevielle D. Pharmacological treatment of generalized anxiety disorders: rationale and limitations. Encephale 33 1 (2007 Jan-Feb) 84-94
9. Clark R.D., Caive J.M., Calais L.A., Qualls C.R., and Tuason V.B. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 12 2 (1999 Apr) 395-401
10. Corbett R., Fielding S., Cornfeldt M., and Dunn R.W. GABAmimetic agents display anxiolitic-like effects in the social interaction and elevated plus maze procedures. Psychopharmocology (Berl) 104 3 (1991) 312-316
11. Coryell W. Panic disorder and mortality. Psychiatr Clin North Am 11 (1988) 433-440
12. Dalvi A., and Rodgers R.J. Anxiolytic effects of valproate and diazepam in mice are differentially sensitive to picrotoxin antagonism. Pharmacol Biochem B 68 1 (2001 Jan) 23-32
13. Davis R., Peters D.H., and McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47 2 (1994) 332-372
14. Davis L.L., Ryan W., Adinoff B., and Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 20 1 Suppl. 1 (2000 Feb) 1S-17S
15. De Angelis L. Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine. Pharmacol Biochem Behav 52 2 (1995 Oct) 329-333
16. First M.B., Spitze R.L., Gibbon M., and Williams J.B.W. Structured clinical interview for DSM-IV Avis I disorders, patient edition (SCID-P), and version 2 (1995), New York State Psychiatric Institute, Biometrics Research, New York
17. Glantz AS. Primer of biostatisties. (Russian translation from English by I.A. Danilov) Moscow, Russia; 1999.
18. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 32 (1959) 50-55 [Medline]
19. Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J Clin Psychiatry 57 Suppl 10 (1996) 11-18
20. Keck Jr. P.E., McElroy S.L., and Friedman L.M. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 12 1 Suppl (1992 Feb) 36S-41S
21. Keck Jr. P.E., Mc Elroy S.L., Tugrul K.C., Bennet J.A., and Smith J.M. Antiepileptic drugs for treatment of panic disorder. Neuropsychobiology 27 3 (1993) 150-153
22. Keck Jr. P.E., Taylor V.E., Tugrul K.C., McElroy S.L., and Bennett J.A. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 33 (1993) 542-546
23. Kinrys G., Pollack M.H., Simon N.M., Worthington J.J., Nardi A.E., and Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 18 3 (2003 May) 169-172
24. Lang A.P., and de Angelis L. Experimental anxiety and antiepileptics: the effects of valproate and vigabatrin in the mirrored chamber test. Methods Find Exp Clin Pharmacol 25 4 (2003 May) 265-271
25. Longo L.P., Campbell T., and Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis 21 2 (2002) 55-64
26. Lum M., Fontaine R., Elie R., and Ontiveros A. Divalproex sodium's antipanic effect in panic disorder. A placebo-controlled study. Biol Psychiatry 27 (1990) 164A-165A
27. Nemeroff C.B. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacology Bull 37 4 (2003) 133-146
28. Ontiveros A., and Fontain R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 17 2 (1992 June) 78-80
29. Pande A.C., Feltner D.E., Jefferson J.W., Davidson J.R., Pollaack M., and Stein M.B. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24 2 (2004) 141-149
30. Primeau F., Fontaine R., and Beauclair L. Valporic acid and panic disorder. Can J Psychiatry 35 (1990) 248-250
31. Raevskii K.S., Aleksandrovekii I., Poiurovslii M.V., Kharlamov A.N., and Neznamov G.G. [Anxiolytic action of sodium valproate (possible for role of gamma-aminobutric acid in affective disorders)-Article in Russian]. Zh Nevropatol Psikiatr Im S S Korsakova 85 4 (1985) 574-579
32. Reed R.C., and Dutta S. What is best strategy for converting from twice-daily divalproex to a once-daily divalproex ER regimen?. Clin Drug Invest 24 9 (2004) 509-521
33. Reoux J.P., Saxon A.J., Malte C.A., Baers J.S., and Sloan K.L. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res 25 9 (2001 Sep) 1324-1329
34. Rodina V.I., Krupina N.A., and Kryzhanovslii G.N. A new natural model of elevated anxiety in rats (article in Russian). Biull Eksp Biol Med 116 8 (1993 Aug) 127-130
35. Roy-Byrne P.P., Ward N.G., and Donnely P.J. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry 50 Suppl (1989 Mar) 44-48
36. Shepard R.A. Behavioral effects of GABA agonists in relation to anxiety and bendiazepline action. Life Sci 40 25 (1987 June 22) 2429-2436
37. Simiand J., Keane P.E., and Morre M. The staircase test in mice: a simple and efficient procedure for primary screening agents. Psychopharmacology (Berl) 84 1 (1984) 48-53
38. Spila B., and Szumillo A. Gabapentin (GBP) in panic disorders-case report. Psychiatr Pol 40 6 (2006 Nov-Dec) 1061-1068
39. Stein D.J., Simeon D., Frenkel M., Islam M.N., and Hollander E. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 56 11 (1995 Nov) 506-510
40. Van Ameringen M., Mancini C., Pipe B., and Bennet M. antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 64 19 (2004) 2199-2220
41. Weissman M.M., Bland R.C., Canino G.J., Faravelli C., Greenwald S., Hwu H.-G., et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54 (1997) 305-309
42. Wittchen H., and Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15 4 (2005) 357-376
43. Woodman C.L., and Noyes Jr. R. Panic disorder: treatment with valproate. J Clin Psychiatry 55 4 (1994 Apr) 134-136